Advanced Practice Providers

Adverse Event Management

Brain Cancer

Breast Cancer

Childhood/AYA Cancer

Disparities in cancer care

Drug Safety

Gastrointestinal Cancer

Genetics

Genitourinary Cancer

Gynecologic Cancers

Head and Neck Cancers

Hematology

Immuno-Oncology

Lung Cancer

Nurse Navigation

Prevention

Radiation Oncology

Sarcomas

Skin Cancer/Melanoma

Supportive Care

Survivorship

Patients with RAS-wild-type metastatic colorectal cancer did not experience a benefit in terms of response rate or survival when cetuximab was added to the first cycle of chemotherapy.

Switch Maintenance Regimens Demonstrate Similar Efficacy for Patients with RAS Wild-Type mCRC

Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP; and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, discuss practice-changing presentations from the 64th American Society of Hematology Annual Meeting and Exposition.

ASH Data Offer Treatment Direction for Oncology Nursing Professionals  

Patients with hepatocellular carcinoma experienced better health-related quality of life outcomes with tislelizumab vs sorafenib.

HRQOL Analysis Favors Tislelizumab Over Sorafenib in Hepatocellular Carcinoma 

Encorafenib plus cetuximab, along with chemotherapy, was linked to antitumor activity and a manageable safety profile in patients with BRAF V600E-mutant metastatic colorectal cancer. 

Encorafenib Triplet Elicits Antitumor Activity in BRAF V600E+ mCRC

News

Latest News

Oncology Drug Crash Course

Media

Insights

Medical World News

Peer Exchange

Podcasts

Videos

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Cancer Insight Summary Slides

Continuing Education

Resources

Contributors

Webinars

Subscribe

Partners

Lindsay Fischer is an editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at lfischer@mjhlifesciences.com

Articles

A study in the Oncology Nursing Forum highlights which factors are associated with positive psychology and symptom burden in colorectal cancer survivors. 

Oncology Nurses Delve Into The Relationship Between Positive Psychology and Symptom Burden in CRC Survivorship

Findings from a phase 2/3 trial found better disease-free and overall survival outcomes with radiation plus docetaxel vs radiation alone in head and neck squamous cell carcinoma.

Adding Docetaxel to Radiation Boosts Survival in Cisplatin-Ineligible HNSCC

Nanvuranlat inspired better progression-free survival in patients with advanced, pretreated refractory biliary tract cancer, meeting the primary end point of a phase 2 trial.

Nanvuranlat Linked To Better PFS Compared With Placebo in Patients With Pretreated, Advanced BTC

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News

Facebook

Twitter

LinkedIn

Specialty

Clinical

Gynecologic Cancer

Sap Partners

1rem

Strategic Alliance Partners

An expert from the University of Colorado (UC Health) comments on ongoing clinical trials which promise to shake up the treatment paradigm of endometrial cancer. 

Potentially Game-Changing Clinical Trials in Endometrial Cancer Seek to Evaluate Immunotherapeutic Approaches

University of Colorado Cancer Center NCI-Designated Comprehensive Cancer Center

University of Colorado Cancer Center NCI-Designated Comprehensive Cancer Center | Strategic Alliance Partners

Latest from University of Colorado Cancer Center NCI-Designated Comprehensive Cancer Center

University of Colorado Cancer Center NCI-Designated Comprehensive Cancer Center | Strategic Alliance Partners

Latest from University of Colorado Cancer Center NCI-Designated Comprehensive Cancer Center

Latest Conference Coverage